Vitiligo pp 153-161 | Cite as

Vitiligo and Skin of Color

  • Onyeka Obioha
  • Candrice Heath
  • Pearl E. Grimes


The prevalence of vitiligo does not differ with respect to different racial and ethnic groups; however the prevalence has been shown to vary in different regions of the world. Given the stark contrast between white patches and normal skin tone in black patients, vitiligo may have distressing psychological impacts in affected individuals and may adversely affect quality of life. Its impact on self-esteem and self-image may be profound. Additionally, the emotional impact on the female population and those with darker skin tones may be more profound. In some geographic areas, social stigma of having vitiligo is very high, and psychiatric morbidity is reported in nearly 75% of affected individuals. According to the psychological and social impact, even the management should be planned and discussed considering combinatory therapies as well as depigmenting approaches not frequently asked by fair-skin patients.


  1. 1.
    Taieb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27–35.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun. 2005;25(Suppl):63–8.CrossRefGoogle Scholar
  3. 3.
    Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–91.CrossRefGoogle Scholar
  4. 4.
    Valia AK, Dutta PK. IADVL text book and atlas of dermatology. Bombay: Bhalani Publishing House; 1996.Google Scholar
  5. 5.
    Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–12.CrossRefGoogle Scholar
  6. 6.
    Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84.CrossRefGoogle Scholar
  7. 7.
    Ezzedine K, Pandya A. Time for a patient-oriented outcome in vitiligo: the vitiligo noticeability scale. Br J Dermatol. 2016;174:255–6.CrossRefGoogle Scholar
  8. 8.
    Porter J. The psychological effects of vitiligo: response to impaired appearance. In: Hann SK, Nordlund JJ, editors. Vitiligo. Oxford, UK: Blackwell Science; 2000. p. 97.CrossRefGoogle Scholar
  9. 9.
    Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol. 2010;35:736.CrossRefGoogle Scholar
  10. 10.
    Pahwa P, Mehta M, Khaitan BK, et al. The psychosocial impact of vitiligo in Indian Patients. Indian J Dermatol Venereol Leprol. 2013;79:679.CrossRefGoogle Scholar
  11. 11.
    Thompson AR, Clarke SA, Newell RJ, et al. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol. 2010;163:481.CrossRefGoogle Scholar
  12. 12.
    Linthorst Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009;61:411.CrossRefGoogle Scholar
  13. 13.
    Ezzedine K, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173:607–9.CrossRefGoogle Scholar
  14. 14.
    Salman A, Kurt E, Topcuoglu V, Demicray Z. Social anxiety and quality of life in vitiligo and acne patients with facial involvement: a cross-sectional controlled study. Am J Clin Dermatol. 2016;17:305–11.CrossRefGoogle Scholar
  15. 15.
    Speeckaert R, Lambert J, van Geel N. Measuring the impact of vitiligo: behind the white spots. J Invest Dermatol. 2016;136:6–7.CrossRefGoogle Scholar
  16. 16.
    Salzes C, Abadie S, Seneschal J, et al. The Vitiligo Impact Patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136:52–8.CrossRefGoogle Scholar
  17. 17.
    Krishna FS, Ramam M, Mehta M, et al. Vitiligo impact scale: an instrument to assess the psychological burden of vitiligo. Indian J Dermatol Venereal Leprol. 2013;79:205–10.CrossRefGoogle Scholar
  18. 18.
    Gupta V, Sreenivas V, Mehta M, et al. Measurement of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol. 2014;171:1084–90.CrossRefGoogle Scholar
  19. 19.
    Ramakrishna P, Rajni T. Psychiatric morbidity and quality of life in vitiligo patients. Indian J Psychol Med. 2014;36:302–3.CrossRefGoogle Scholar
  20. 20.
    Taylor SC, Heath C. Cultural competence and unique concerns in patients with ethnic skin. J Drugs Dermatol. 2012;11:460–5.PubMedGoogle Scholar
  21. 21.
    Lilly E, Lu PD, Borovicka JH, et al. Development and validation of a vitiligo-specific quality of life instrument (VitiQoL). J Am Acad Dermatol. 2013;69:e11–8.CrossRefGoogle Scholar
  22. 22.
    Boza JC, Kundu RV, Fabbrin A, Horn R, et al. Translation, cross-cultural adaptation and validation of the vitiligo-specific health-related quality of life instrument (VitiQoL) into Brazilian Portuguese. An Bras Dermatol. 2015;90:358–62.CrossRefGoogle Scholar
  23. 23.
    Fain PR, Gowan K, LaBerge GS, et al. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet. 2003;72:1560–4.CrossRefGoogle Scholar
  24. 24.
    Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16:208–14.CrossRefGoogle Scholar
  25. 25.
    Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Postepy Dermatol Alergol. 2014;31:247.CrossRefGoogle Scholar
  26. 26.
    Chen H, Huang W, Gut JP, et al. A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet. 2005;76(6):1057–65.CrossRefGoogle Scholar
  27. 27.
    Grimes PE, Halder RM, Jones C, et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol. 1983;119:300.CrossRefGoogle Scholar
  28. 28.
    Dash R, Mohapatra A, Man-Junathswamy BS. Anti-thyroid peroxidase antibody in vitiligo: a prevalence study. J Thyroid Res. 2015;2015:1–8.CrossRefGoogle Scholar
  29. 29.
    Adorini L, Penna G. Control of autoimmune disease by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4:404–12.CrossRefGoogle Scholar
  30. 30.
    Brilea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of Vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008;9(4):345–59.CrossRefGoogle Scholar
  31. 31.
    Li K, Shi Q, Yang L, Li X, Liu L, Wang L, et al. The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo. Br J Dermatol. 2012;167:815–21.CrossRefGoogle Scholar
  32. 32.
    Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62:937–4.CrossRefGoogle Scholar
  33. 33.
    Saleh HM, Abdel Fattah NS, Hamza HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. Photodermatol Photoimmunol Photomed. 2013;29(1):34–40.CrossRefGoogle Scholar
  34. 34.
    Doss RW, El-Rafail AA, Gohary YM, Rashed LA. Vitimin D receptor expression in vitiligo. Int J Dermatol. 2015;60:544–8.Google Scholar
  35. 35.
    Grimes PE. Vitiligo. In: Taylor SC, Kelly AP, Lim HW, Serrano AMA, editors. Taylor and Kelly’s dermatology for skin of color. New York, NY: McGraw-Hill; 2016. p. 341–50.Google Scholar
  36. 36.
    Gan EY, Cario-André M, Pain C, Goussot JF, Taïeb A, Seneschal J, Ezzedine K. Follicular vitiligo: a report of 8 cases. J Am Acad Dermatol. 2015;74:1178–84.CrossRefGoogle Scholar
  37. 37.
    Ezzedine K, Mahé A, van Geel N, Cardot-Leccia N, Gauthier Y, Descamps V, Al Issa A, Ly F, Chosidow O, Taïeb A, Passerson T. Hypochromic vitiligo: delineation of a new entity. Br J Dermatol. 2014;172:716–21.CrossRefGoogle Scholar
  38. 38.
    Hann SK, Kim YS, Yoo JH, Chun YS. Clinical and histopathologic characteristics of trichrome vitiligo. J Am Acad Dermatol. 2000;42(4):589–96.CrossRefGoogle Scholar
  39. 39.
    Di Chiacchio NG, Ferreira FR, de Alvarenga ML, Baran R. Nail trichrome vitiligo: a case report and literature review. Br J Dermatol. 2013;168(3):668–9.CrossRefGoogle Scholar
  40. 40.
    Lee DY, Kim CR, Lee KH. Trichrome vitiligo in segmental type. Photodermatol Photoimmunol Photomed. 2011;27(2):111–2.CrossRefGoogle Scholar
  41. 41.
    Silverberg JI, Silverberg NB. Topical tacrolimus is more effective for treatment of vitiligo in patiens of skin of color. J Drugs Dermatol. 2011;10:507–10.PubMedGoogle Scholar
  42. 42.
    Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy psoralen UVA therapy versus narrowband UVB therapy. Arch Dermatol. 2007;143:578–84.CrossRefGoogle Scholar
  43. 43.
    Bhatnagar A, Kanwar AJ, Parsad D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21:638–42.CrossRefGoogle Scholar
  44. 44.
    Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56:274–8.CrossRefGoogle Scholar
  45. 45.
    Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well tolerated therapy. Int J Dermatol. 2005;44:57–60.CrossRefGoogle Scholar
  46. 46.
    Kanwar AJ, Dogra S. Narrow-band UVB for the treatment of generalized vitiligo in children. Clin Exp Dermatol. 2005;30:332–6.CrossRefGoogle Scholar
  47. 47.
    Chen GY, Hsu MM, Tai HK, Chou TC, Tseng CL, Chang HY, et al. Narrow-band UVB treatment of vitiligo in Chinese. J Dermatol. 2005;32:793–800.CrossRefGoogle Scholar
  48. 48.
    Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. JAMA Dermatol. 2013;149:68–73.CrossRefGoogle Scholar
  49. 49.
    Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151(1):42–50.CrossRefGoogle Scholar
  50. 50.
    Alghamdi KM, Kumar A. Depigmentation therapies for normal skin in vitiligo universalis. J Eur Acad Dermatol Venereol. 2011;25:749–57.CrossRefGoogle Scholar
  51. 51.
    Gupta D, Kumari R, Thappa DM. Depigmentation therapies in vitiligo. Indian J Dermatol Venereol Leprol. 2012;78:49–58.CrossRefGoogle Scholar
  52. 52.
    Hariharan V, Klarquist J, Reust M, et al. Monobenzylether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiologic responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol. 2010;130:211–20.CrossRefGoogle Scholar
  53. 53.
    Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. Br J Dermatol. 1977;97:669–79.CrossRefGoogle Scholar
  54. 54.
    Grimes PE, Nashawati R. The Role of Diet and Supplements in Vitiligo Management. Dermatol Clin. 2017Apr;35(2):235–243..Google Scholar
  55. 55.
    Tan ES, Sarkany R. Topical monobenzyl ether of hydroquinone is an effective and safe treatment for depigmentation of extensive vitiligo; a retrospective cohort of 53 cases. Br J Dermatol. 2015;172:166.2–166.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Onyeka Obioha
    • 1
  • Candrice Heath
    • 1
  • Pearl E. Grimes
    • 1
  1. 1.Vitiligo & Pigmentation Institute of Southern CaliforniaLos AngelesUSA

Personalised recommendations